Skip to content

Comparison of Frailty Screening Performance and Predictive Validity of Adverse Health Outcomes in Breast Cancer Patients Using Frailty Screening Tools

Comparison of Frailty Screening Performance and Predictive Validity of Adverse Health Outcomes in Breast Cancer Patients Using Frailty Screening Tools

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06467149
Acronym
frailty
Enrollment
500
Registered
2024-06-20
Start date
2023-08-12
Completion date
2025-12-30
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frailty Syndrome

Brief summary

This study uses the Physical Frailty Phenotype (PFP) as the diagnostic criterion for frailty and aims to explore the frailty screening scale FRAIL (The FRAIL Scale), Tilburg Frailty Index (TFI) and geriatric screening. Screening performance of Tool-8 (Geriatric-8, G-8) in breast cancer patients, to compare the predictive validity of different frailty screening scales for adverse health outcomes in breast cancer patients, and to select appropriate frailty screening methods for breast cancer patients in my country Screening scale.

Interventions

None listed

Sponsors

Ministry of Education, China
CollaboratorOTHER_GOV
Ju Qiu
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of breast cancer * Age ≥50 years old * the treatment plan discussed by MDT includes surgery and chemotherapy * can walk on their own (with the assistance of walking aids)

Exclusion criteria

* Communication disorders * Mental disorders that can't cooperate normally * Combined with other malignant tumours * Terminal stage of the disease

Design outcomes

Primary

MeasureTime frameDescription
FallsFrom 2023.8~2025.12.one or more falls due to various reasons between the diagnosis of breast cancer and the second follow-up period.Does not use any scale, is a dichotomous variable with a fall score of 1 and a no fall score of 0.
Unplanned hospitalisation2023.8~2025.12.hospitalisation after doctor's diagnosis and hospitalisation for more than one day after diagnosis of breast cancer up to the second follow-up period, except for treatment nodes such as surgery and chemotherapy.No scale is used, it is a dichotomous variable with a score of 1 for unplanned hospitalisation and a score of 0 for non-occurrence.
DisabilityFrom 2023.8~2025.12.Activities of daily living (ADL) were assessed using the Barthel Index (BI).The present study defined the development of disability as a decrease in scores on at least one scale entry in the BI scale from six months earlier
DepressionFrom 2023.8~2025.12.Depression screening was performed using the Geriatric Depression Scales-5 (GDS-5). The options for each entry were yes or no. Entry 1 was scored 0 points for yes and 1 point for no, and entries 2 to 5 were scored 1 point for yes and 0 points for no. The answer yes for entries 2 to 5 is 1 point, and the answer no is 0 points. The total score ranged from 0 to 5, with a score of ≥2 indicating the presence of depression.

Countries

China

Contacts

Primary Contactju qiu, Bachelor.
qiujuchongyi@163.com18523569369
Backup Contactlin zeng

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026